fbpx Psychedelics Research | Faculty of Health Sciences | Queen's University | Faculty of Health Sciences | Queen's University Skip to main content

Psychedelics Research

  • Decorative Image
    Call for Members:
    Psychedelic Science Advisory Committee
  • Decorative Image
    Psychedelics Research


Psychedelic-assisted therapies have resulted in transformative experiences for many individuals, as well as the practitioners who have worked with them. However, despite the wealth of anecdotal evidence gathered to date, the scientific basis for the use of psychedelics remains somewhat limited. In addition to the need for more basic science about how psychedelics work on the brain, psychedelic-assisted therapies will benefit from the development of best practice standards, modernized regulatory policy, practitioner training, and public education.
 

Queen’s Health Sciences plans to be a leader in this field. As such, the Faculty has created a research collaborative that will serve as an interdisciplinary space for research, innovation and knowledge translation in the field of psychedelics. The collaborative will serve as a space to connect expertise across campus and stakeholders and partners in the broader community.

The Dimensions Health Research Collaborative will take a multi-pronged approach to supporting research and innovation in psychedelic-focused therapies. In addition to bringing together collaborators from across the university, the collaborative will allow the faculty to build relationships with stakeholders and experts in the community.

Anticipated benefits include: 

  • Furthering existing research and broadening the scope of psychedelic-assisted therapies and the psychedelics sector 
  • Building awareness of the healing potential of psychedelics, and supporting early entry into the scientific and regulatory landscape; 
  • Laying a foundation for the development of policy that is ethical and evidence-informed;
  • Supporting training, education, and knowledge translation for healthcare providers;
  • Aiding the development of best practice standards to ensure the safety, quality, and effectiveness of therapies, helping to ensure the sector’s long-term growth and sustainability

 The collaborative will be aligned with Faculty of Health Sciences' commitment to supporting Black, Indigenous and People of Colour (BIPOC) learners, staff and faculty, and the Equity, Diversity and Inclusion (EDI) initiative, launched in fall 2020. 

The collaborative was founded with support from the Dimensions Health Fund in support of the Study of Psychedelics, established by Dimensions Health Centres (“Dimensions”). For further information on the collaborative, including opportunities to partner, please contact David Clements, executive director, psychedelics research, at dmc14@queensu.ca.

New & Announcements

Call for Members: Psychedelic Science Advisory Committee

December 15, 2021

The Dimensions Health Research collaborative is currently seeking volunteer members for its inaugural Psychedelic Science Advisory Committee, which will provide advice to the Collaborative on science matters related to the field of psychedelics and human health. This includes the pursuit of pre-clinical and clinical research, as well as translational research, implementation science, and health services and policy research.

Potential members should provide a brief CV and cover letter to the Executive Director, Psychedelics Research, by January 31, 2022. Terms of Reference for the committee can be found here

Members will be chosen based on a broad array of factors including academic background, membership in scientific and health professional societies, and track record in fields related to the area of psychedelic research, and/or treatment.

The committee will have relevant expertise and experience, and a variety of perspectives, aligning with Faculty commitments in the area of equity, diversity and inclusion.In addition, membership of the Committee will reflect the value of various areas of expertise, knowledge, and perspectives, including health professionals, scientists, entrepreneurs, patients, and community members.

The committee’s collective expertise will include, but not be limited to:

  • Clinical trial design
  • Neuroscience
  • Psychiatry
  • Psychology
  • Pharmacology
  • Medicinal chemistry
  • Medicine
  • Health services and policy research
  • Regulatory science
  • Palliative medicine
  • Biochemistry
  • Physiology
  • Public health

The committee will have has at least six core members and will not exceed ten. Members are appointed for an initial two-year term, which may be extended for an additional two years. Membership may be periodically adjusted to ensure the appropriate representation of expertise and experience.

Mr. Clements earned a BA at the University of Victoria, as well as an MPA from the School of Policy Studies at Queen’s, with a concentration in health policy. He also pursued doctoral studies at the Vrije Universiteit Amsterdam.

Ron Shore appointed as research scientist with the Dimensions Health Research Collaborative

David Clements

December 15, 2021

Queen’s Health Sciences is pleased to announce the appointment of Ron Shore as research scientist with the Dimensions Health Research Collaborative, effective December 6, 2021.

Ron Shore (he/him) is a doctoral candidate in the School of Kinesiology and Health Studies, where he has taught as an adjunct, continuing adjunct and teaching fellow for 15 years. Ron is also a part-time Professor at the University of Ottawa, where he teaches Psychedelics, Politics and Harm reduction to both graduate and undergraduate students.

Ron's PhD research is on the clinical application of psilocybin. He has several forthcoming papers from his doctoral research including: Mapping Psilocybin Therapy, a Scoping Review, Behavioural Investigations of Psilocybin in Animals: A Scoping Review, and Psychedelics, Safety and Clinical Trial Design.

Ron has a B.A. in philosophy and Masters in Public Administration (concentration in health policy) both from Queen's, and is the founder of Kingston's Street Health Centre. Ron spent 23 years in front-line harm reduction, community and public health prior to returning to school for his PhD, which he defends in early 2022.

David Clements appointed Executive Director, Psychedelics Research 

David Clements

June 1, 2021

Dr. Jane Philpott, Dean, Faculty of Health Sciences at Queen’s University, has appointed David Clements as Executive Director, Psychedelics Research, effective June 1, 2021. In this part-time role, he will work closely with scientists and stakeholders at Queen’s, in the Kingston community, and beyond. Mr. Clements will serve concurrently as senior advisor, innovation strategy and policy, for the faculty. 

Queen’s contributions in this area include the launch of a psychedelics research collaborative, enabled by the Dimensions Health Fund in support of the Study of Psychedelics, established by Dimensions Health Centres (“Dimensions”). The collaborative will serve as a space to connect expertise across campus and stakeholders and partners in the broader community. 

Mr. Clements has more than two decades experience working in health policy, planning, strategy, communications and stakeholder engagement. Her has held senior management roles in organizations including Health Canada, the Canadian Institutes of Health Research, the Canadian Institute for Health Information and the Canadian Health Services Research Foundation. In 2014 and 2015, he served as executive director of the federal advisory panel on healthcare innovation, and he has also served as a senior advisor and communications director for Canada’s minister of health. 

Mr. Clements earned a BA at the University of Victoria, as well as an MPA from the School of Policy Studies at Queen’s, with a concentration in health policy. He also pursued doctoral studies at the Vrije Universiteit Amsterdam.